JPMorgan published a research report stating that it has assigned a "Shareholding" rating to SKB BIO-B (06990.HK) with a Target Price of 240 yuan. Established in 2016, SKB BIO currently has an antibody-drug conjugate (ADC) SKB264 in the Chinese market, and eight ADCs undergoing clinical trials, along with three non-ADC cancer drugs in the new drug application (NDA) approval process in China.

Morgan also mentioned that Merck (MRK.US) holds the development, use, manufacturing, and commercialization rights for SKB264 outside the Greater China region and has initiated 10 global Phase III trials for SKB264, covering a broader range of indications than its competitors. Therefore, the firm estimates that the potential peak sales of SKB264 in China may exceed 8 billion yuan, while peak sales outside China could reach 6 billion dollars.